MEDP vs MYGN Valuation Comparison 2026 — Intrinsic Value Analysis

Quick Summary — MEDP scores higher on quality with 10.0/10 vs MYGN's 6.6/10. MEDP trades at $445.59 while MYGN trades at $4.31. Both analyzed daily using SEC EDGAR data across 13 institutional models.

MEDP

Diagnostics & Research

Medpace Holdings, Inc.

Quality

10.0

out of 10

Value Trap

6

SAFE

Price

$445.59

Last close

Models

11/13

Active

VS

MYGN

Diagnostics & Research

Myriad Genetics, Inc.

Quality

6.6

out of 10

Value Trap

24

SAFE

Price

$4.31

Last close

Models

12/13

Active

MEDP

Quality Score 10.0/10 — top tier

Limited to 2/13 visible models

MYGN

Earnings Power Value sees +278.8% upside

Limited to 2/13 visible models

MEDP vs MYGN — Fair Value Comparison

MEDP

MYGN

Market Price Model 1 Model 2

Model-by-Model Comparison

Model	Type	MEDP Fair Value	MEDP Upside	MYGN Fair Value	MYGN Upside
Bayesian DCF	Intrinsic	$389.44	-12.6%	$0.06	-98.6%
Earnings Power Value	Intrinsic	$195.85	-56.0%	$16.33	+278.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

MEDP vs MYGN — Which Stock Is More Undervalued in 2026?

MEDP scores higher with a 10.0/10 quality rating vs MYGN's 6.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do MEDP and MYGN Valuations Compare?

At $445.59, MEDP trades +12.6% above its Bayesian DCF fair value of $389.44, while MYGN at $4.31 trades +98.6% above its estimate of $0.06. MYGN shows a wider gap between price and intrinsic value.

Quality of Company: MEDP vs MYGN

MEDP earns a Quality of Company score of 10.0/10 compared to MYGN's 6.6/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: MEDP vs MYGN

MEDP carries a SAFE value trap risk (6/100) while MYGN shows SAFE risk (24/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.

Both in Diagnostics & Research

Both MEDP and MYGN operate in Diagnostics & Research, which has 48 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare MEDP vs MYGN differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

MEDP

View Full Medpace Holdings, Inc. Analysis →

MYGN

View Full Myriad Genetics, Inc. Analysis →

See all Diagnostics & Research stocks →